Zimbabwe has turned down a significant US health deal worth $367m (272 million pounds) spanning five years due to the United States' demand for confidential data.
The decision came to light following a official document from December was disclosed, revealing that President Emmerson Mnangagwa believed the agreement was "unbalanced".
A government representative has since stated that the US was requesting genetic material for research and profit but refused to guarantee the benefits from future medical innovations.
"We must now begin the challenging and unfortunate task of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had provided more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged continued negotiations to secure a deal suitable to both sides so the nation's critical HIV programme can continue.
Wider Background
This rejection comes after a similar case in neighbouring Kenya, where a high court blocked a similar health funding agreement following legal challenges were filed about the safety of Kenyans' health data.
After resuming the presidency last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had administered assistance for the US government, but Trump argued its expenditure was "inefficient" and his administration was seeking government-to-government deals to enhance transparency and responsibility.
Based on statements, 16 African countries have so far agreed to these new health pacts, representing over $18.3bn of fresh investment.
Details of the Declined Agreement
The money for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership could have provided extraordinary advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently on HIV treatment via American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Zimbabwe was being asked to share its biological resources and data indefinitely, with no corresponding assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that provided information," his statement read.
"In essence, our nation would supply the basic resources for medical research without any certainty that the final treatments would be accessible to our population if a future pandemic emerge."
National Interest and Global Health
Mangwana further said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were disrupting frameworks previously established through the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme created to deal with potential global health emergencies.
"This framework is intended to ensure that when a nation provides its samples, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the resources to create them."
These objections over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We welcome further discussions with our US partners on how future co-operation could be designed in a manner that respects the independence and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the government's concerns, but suggested that negotiations should continue given that much of the country's Aids initiatives were funded by foreign aid.
"If technical issues exist, such as those relating to data governance or implementation frameworks, these can often be resolved through detailed discussion and negotiated safeguards," it said.
The halted deal emphasises the complex tensions between receiving crucial international aid and safeguarding local interests in an ever more data-driven world.